APA (7th ed.) Citation

Ricciuto, A., Liu, K., El‐Matary, W., Amin, M., Amir, A. Z., Aumar, M., . . . Lee, C. (2024). Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium. Alimentary Pharmacology & Therapeutics, 59(10), 1236. https://doi.org/10.1111/apt.17936

Chicago Style (17th ed.) Citation

Ricciuto, Amanda, et al. "Oral Vancomycin Is Associated with Improved Inflammatory Bowel Disease Clinical Outcomes in Primary Sclerosing Cholangitis‐associated Inflammatory Bowel Disease (PSC‐IBD): A Matched Analysis from the Paediatric PSC Consortium." Alimentary Pharmacology & Therapeutics 59, no. 10 (2024): 1236. https://doi.org/10.1111/apt.17936.

MLA (9th ed.) Citation

Ricciuto, Amanda, et al. "Oral Vancomycin Is Associated with Improved Inflammatory Bowel Disease Clinical Outcomes in Primary Sclerosing Cholangitis‐associated Inflammatory Bowel Disease (PSC‐IBD): A Matched Analysis from the Paediatric PSC Consortium." Alimentary Pharmacology & Therapeutics, vol. 59, no. 10, 2024, p. 1236, https://doi.org/10.1111/apt.17936.